Find clinical trials for kidney cancer in the United Kingdom. Explore treatment pathways including immunotherapy, targeted therapy, and surgery.
Kidney cancer affects ~13,000 people per year in the UK, with renal cell carcinoma (RCC) being the most common type. Clear cell RCC accounts for ~75% of cases. Many kidney cancers are found incidentally during imaging for other reasons. Early-stage disease has excellent outcomes with surgery alone, while advanced kidney cancer has been transformed by immunotherapy and targeted therapy.
Early stage: partial or radical nephrectomy (surgery). Advanced/metastatic: first-line treatment now uses immunotherapy combinations - nivolumab + ipilimumab, or pembrolizumab + axitinib, or avelumab + axitinib. Single-agent TKIs (tyrosine kinase inhibitors) like sunitinib or pazopanib are alternatives. Second-line: nivolumab, cabozantinib, lenvatinib + everolimus, or tivozanib (recently approved by NICE).
Active UK kidney cancer trials: next-generation immunotherapy combinations, bispecific antibodies, ADCs (antibody-drug conjugates), CAR-T cell therapy targeting carbonic anhydrase IX, neoadjuvant immunotherapy (before surgery), and active surveillance strategies. The NHS has specialist kidney cancer centres with dedicated surgical and medical oncology teams.
19 recruiting trials — 1 early-stage, 7 recurrent or metastatic, 11 stage not specified
Free AI-powered matching - no signup required
Search renal cell carcinoma Trials →